Trastuzumab deruxtecan (T-DXd) has been approved to treat various tumors. While most adverse events (AEs) associated with T-DXd are manageable, interstitial lung disease (ILD)/pneumonitis is a notable AE of special concern. This review describes the incidence, severity, and management of T-DXd-induced ILD/pneumonitis across different tumors. We conducted a systematic search of PubMed, Embase, Cochrane Library, and Web of Science for literature published up to 13 September 2024, regarding the use of T-DXd in the treatment of HER2-positive tumors. Studies included were clinical trials involving HER2-positive tumors with reported ILD/pneumonitis cases.The main data extracted from the full-text articles included the incidence and severity of T-DXd-induced ILD. 18 studies involving 3380 patients with various advanced solid malignancies were included in our review. The overall incidence of adjudicated drug-related ILD/pneumonitis was 12.40%. Although most ILD/pneumonitis cases were low-grade, the risk of ILD/pneumonitis-related death should not be overlooked. Given the prolonged exposure to the drug, careful monitoring and management of T-DXd-induced ILD/pneumonitis are critical. Management strategies include dose reduction, treatment interruption, discontinuation, corticosteroids, and supportive care. Further research is needed to clarify the risk factors and mechanisms underlying T-DXd-induced ILD/pneumonitis. This review highlights critical gaps in understanding the risk factors and mechanisms of T-DXd-induced ILD, underscoring the need for further research.
9 November 2023 in Cardiovascular Drugs and Therapy
Background: Ki-67 is a key indicator of the proliferation activity of tumors. However, no standardized criterion has been established for Ki-67 index calculation. Scale-invariant feature transform (SIFT) algorithm can identify the robust invariant features to rotation, translation, scaling and linear intensity changes for matching and registration in computer vision. Thus, this study aimed to develop a SIFT-based computer-aided system for Ki-67 calculation in breast cancer. Methods: Hematoxylin and eosin (HE)-stained and Ki-67-stained slides were scanned and whole slide images (WSIs) were obtained. The regions of breast cancer (BC) tissues and non-BC tissues were labeled by experienced pathologists. All the labeled WSIs were randomly divided into the training set, verification set, and test set according to a fixed ratio of 7:2:1. The algorithm for identification of cancerous regions was developed by a ResNet network. The registration process between paired consecutive HE-stained WSIs and Ki-67-stained WSIs was based on a pyramid model using the feature matching method of SIFT. After registration, we counted the nuclear-stained Ki-67-positive cells in each identified invasive cancerous region using color deconvolution. To assess the accuracy, the AI-assisted result for each slice was compared with the manual diagnosis result of pathologists. If the difference of the two positive rate values is not greater than 10%, it was a consistent result; otherwise, it was an inconsistent result. Results: The accuracy of the AI-based algorithm in identifying breast cancer tissues in HE-stained slides was 93%, with an area under the curve (AUC) of 0.98. After registration, we succeeded in identifying Ki-67-positive cells among cancerous cells across the entire WSIs and calculated the Ki-67 index, with an accuracy rate of 91.5%, compared to the gold standard pathological reports. Using this system, it took about 1 hour to complete the evaluation of all the tested 771 pairs of HE- and Ki-67-stained slides. Each Ki-67 result took less than 2 seconds. Conclusions: Using a pyramid model and the SIFT feature matching method, we developed an AI-based automatic cancer identification and Ki-67 index calculation system, which could improve the accuracy of Ki-67 index calculation and make the data repeatable among different hospitals and centers.
24 February 2024 in Cardiovascular Drugs and Therapy
CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become the standard of care for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC). However, real-world data from China’s central regions remain limited. This study aimed to evaluate the real-world treatment patterns and efficacy of CDK4/6i in HR+/HER2− MBC patients across the Dongting Lake region in China. This multicenter retrospective study included 590 HR+/HER2− MBC patients treated with CDK4/6i between 2016 and 2025 in five tertiary cancer centers in the Dongting Lake area of Hunan province, China. Patient demographics, treatment patterns, progression-free survival (PFS), and prognostic factors were analyzed. Among 616 initially screened patients, 590 met eligibility criteria. Of these, 63.39% received CDK4/6i as first-line treatment and 25.59% as second-line. The most commonly used CDK4/6i were abemaciclib (33.39%), dalpiciclib (28.98%), palbociclib (25.76%), and ribociclib (10.85%). Median PFS was significantly longer in the first-line group than in the second-line group (32.3 vs. 17.6 months, P<0.001). While the objective response rate (ORR) was numerically higher in the first-line setting (49.52% vs. 42.31%), only the disease control rate (DCR) showed statistical significance (97.14% vs. 91.03%). Multivariate Cox analysis identified several independent predictors of shorter PFS: de novo stage IV disease (HR =1.50), Ki-67 ≥30% (HR =1.60), liver metastasis (HR =2.26), lung metastasis (HR =1.53), and use of CDK4/6i as second-line (HR =2.24), while disease-free interval ≥5 years was protective (HR =0.65, P=0.01). CDK4/6i demonstrates favorable real-world efficacy in HR+/HER2− MBC patients in central China, particularly in the first-line setting. Several clinical factors may aid in treatment selection and risk stratification.
Piezocatalytic therapy (PCT) harnesses mechanical energy to generate tumor‐lethal reactive oxygen species (ROS), but its efficacy is limited by rapid electron‐hole recombination and poor intratumoral retention. To overcome these limitations, we engineered heterostructured BiOCl@CuO nanosheets embedded in an injectable, conductive, thermosensitive hydrogel composed of Pluronic F127 (F127) and reduced graphene oxide (rGO), with rGO specifically enhancing the hydrogel's mechanical strength and conductivity, for the combinational treatment of breast cancer. Under ultrasound (US) stimulation, BiOCl@CuO establishes a strong interfacial electric field that enhances charge separation and accelerates the generation of ROS. In addition, near‐infrared (NIR) irradiation activates BiOCl@CuO to convert light into heat, elevating intratumoral temperature and further amplifying ROS‐mediated cytotoxicity while enabling photothermal therapy (PTT). The integrated BiOCl@CuO/F127@rGO hydrogel exhibits rapid sol–gel transition at physiological temperature, robust tissue adhesion, and sustained local retention. In vitro, the synergistic therapy induced marked ROS bursts and achieved 60% breast cancer cell ablation at 50 µg/mL with less than 10% toxicity to normal cells. In vivo, orthotopic breast tumors treated with US+NIR showed 90% regression, reduced proliferation and angiogenesis, activation of apoptotic and immunogenic cell death pathways, and favorable biocompatibility. Critically, the regimen triggered robust local immune activation, increasing intratumoral CD8 + T cell infiltration by 2.7‐fold and IFN‐γ secretion by 5‐fold while upregulating DC maturation markers (CD80/CD86+) by 3‐fold. This work establishes a precise, minimally invasive strategy that couples piezocatalysis with photothermal conversion for effective breast cancer therapy.